The Effect of Electronic Health Record Use and Patient-Centered Communication on Cancer Screening Behavior: An Analysis of the Health Information National Trends Survey

J Health Commun. 2017 Jul;22(7):554-561. doi: 10.1080/10810730.2017.1338801. Epub 2017 Jul 6.

Abstract

The present study used the 2013 Health Information National Trends Survey (N = 3185) to examine the effects of patient-centered communication (PCC) and the use of electronic health records (EHRs) on the likelihood of patients receiving a recommended screening for cancer (i.e., mammogram, PSA test). Self-determination theory, a framework of self-initiated extrinsic behaviors, was applied to test mediation models of PCC and EHR use, respectively, through patient activation. The results demonstrated that PCC and EHR use predicted cancer screening (mediated through patient activation), but only for women recommended for biannual mammograms. The aforementioned relationship was not found for men who are recommended for prostate cancer screening. PCC and EHRs do appear to facilitate a patient's ability to take care of their own health, but only under certain circumstances. It was additionally found that men were more likely to report higher degrees of physician PCC when their physicians maintained an EHR, whereas women reported no difference. Future research should examine more nuanced personality factors that affect the perception of PCC in the presence of EHRs and the relationship between men's activation and likelihood of receiving a cancer screen.

MeSH terms

  • Aged
  • Breast Neoplasms / diagnosis
  • Communication*
  • Early Detection of Cancer / psychology*
  • Early Detection of Cancer / statistics & numerical data
  • Electronic Health Records / statistics & numerical data*
  • Female
  • Health Care Surveys
  • Humans
  • Male
  • Mammography / statistics & numerical data
  • Middle Aged
  • Patient-Centered Care*
  • Physician-Patient Relations*
  • Prostate-Specific Antigen / blood
  • Prostatic Neoplasms / diagnosis
  • United States

Substances

  • Prostate-Specific Antigen